A Phase 1 Study of MQ710 in People With Solid Tumors


Full Title

A First In Human Phase I, Open Label, Safety And Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, A Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination with The Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors


In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.

MQ710 is a type of immunotherapy. It is made to kill tumor cells directly as well as boost your own immune system to fight cancer. It is injected directly into tumors.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a solid tumor cancer that came back or kept growing after at least two prior regimens of treatment.
  • Have two or more tumors that are in a place where they can be injected with MQ710. Examples of tumors to be treated include squamous cell skin cancer, basal cell carcinoma, melanoma, and Merkel cell carcinoma. Other tumors to be treated include sebaceous carcinoma, Paget’s disease, Kaposi sarcoma, head and neck cancers, adnexal carcinoma, and angiosarcoma.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • This study is for people age 18 and older.


For more information and to see if you can join this study, please contact Dr. Lara Dunn’s office at 646-608-3787.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID